SCHEMBL830168

SCHEMBL830168

O=c1oc2ccc(Br)cc2cc1S(=O)(=O)/C=C\c1ccc(Cl)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
LMNA P02545 5/20 0.47
PKM P14618 3/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAOB P27338 2/20 0.43
FBP1 P09467 1/20 0.40
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 3/20 0.39
TP53 P04637 2/20 0.39
POLB P06746 2/20 0.39
MCL1 Q07820 2/20 0.39
STAT3 P40763 1/20 0.39
RAB9A P51151 1/20 0.39
GPR35 Q9HC97 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829694 1.00 CA12 (0.52) CA12CA1CA2CA9LMNA
SCHEMBL829695 1.00 CA12 (0.52) CA12CA1CA2CA9LMNA
SCHEMBL829341 0.92 CA1 (0.58) CA12CA1CA2CA9KMT2A
SCHEMBL831227 0.92 CA1 (0.58) CA12CA1CA2CA9KMT2A
SCHEMBL829340 0.92 CA1 (0.58) CA12CA1CA2CA9KMT2A
SCHEMBL830306 0.85 CA12 (0.55) CA12CA1CA2CA9LMNA
SCHEMBL830919 0.85 CA12 (0.55) CA12CA1CA2CA9LMNA
SCHEMBL830307 0.85 CA12 (0.55) CA12CA1CA2CA9LMNA
SCHEMBL830577 0.78 MAPT (0.37) LMNAKMT2AMEN1NPSR1FBP1
SCHEMBL830597 0.78 MAPT (0.37) LMNAKMT2AMEN1NPSR1FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US claimed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP disclosed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 CA12 2448/4885CA1 3859/4885CA2 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.